Pharmacogenetics of Type 2 Diabetes-Progress and Prospects.
Pharmacogenetics of Type 2 Diabetes-Progress and Prospects.
复制标题
DOI:
10.3390/ijms21186842
复制
发表时间:
2020-09-18
影响因子:
5.6
通讯作者:
Glotov AS
中科院分区:
文献类型:
--
作者:
Nasykhova YA;Tonyan ZN;Mikhailova AA;Danilova MM;Glotov AS
Type 2 diabetes mellitus (T2D) is a chronic metabolic disease resulting from insulin resistance and progressively reduced insulin secretion, which leads to impaired glucose utilization, dyslipidemia and hyperinsulinemia and progressive pancreatic beta cell dysfunction. The incidence of type 2 diabetes mellitus is increasing worldwide and nowadays T2D already became a global epidemic. The well-known interindividual variability of T2D drug actions such as biguanides, sulfonylureas/meglitinides, DPP-4 inhibitors/GLP1R agonists and SGLT-2 inhibitors may be caused, among other things, by genetic factors. Pharmacogenetic findings may aid in identifying new drug targets and obtaining in-depth knowledge of the causes of disease and its physiological processes, thereby, providing an opportunity to elaborate an algorithm for tailor or precision treatment. The aim of this article is to summarize recent progress and discoveries for T2D pharmacogenetics and to discuss the factors which limit the furthering accumulation of genetic variability knowledge in patient response to therapy that will allow improvement the personalized treatment of T2D.
登录
查看更多内容
影响因子:
16.2
作者:
Buse, John B.;Wexler, Deborah J.;Davies, Melanie J.
通讯作者:
Davies, Melanie J.
影响因子:
8.2
作者:
Qin, Wen;Zhang, Rong;Hu, Cheng;Wang, Cong-rong;Lu, Jing-yi;Yu, Wei-hui;Bao, Yu-qian;Xiang, Kun-san;Jia, Wei-ping
通讯作者:
Jia, Wei-ping
影响因子:
3.8
作者:
Brown, Audrey E.;Yeaman, Stephen J.;Walker, Mark
通讯作者:
Walker, Mark
DOI:
10.1111/j.1440-1681.2012.05701.x
发表时间:
2012-05-01
影响因子:
2.9
作者:
Dai, Xing-Ping;Huang, Qiong;Liu, Zhao-Qian
通讯作者:
Liu, Zhao-Qian
影响因子:
6.9
作者:
de Miguel-Yanes, Jose M.;Manning, Alisa K.;Meigs, James B.
通讯作者:
Meigs, James B.